Artivion vs AtriCure
AORT and ATRC side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AORT and ATRC compare
AtriCure is the larger company, worth 3.1 times as much as Artivion ($2.9B against $931M).
Artivion grew revenue faster over the last twelve months (14.0% versus 13.8% for AtriCure).
AtriCure keeps more of each dollar of sales as profit, with a net margin of 2.5% compared with −3.7% at Artivion.
AtriCure scores higher on the StockData Score (12 against 8 for Artivion), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AORT | ATRC |
|---|---|---|
| Size and price | ||
| Market cap | $931M | $2.9B |
| Share price | $19.10 | $56.84 |
| Change, 1 year | −59.9% | 71.9% |
| Change, 5 years | 0.79% | −26.8% |
| Beta (5Y) | 1.15 | 1.26 |
| Employees | 1,800 | 1,350 |
| StockData Score | ||
| Total score | 8 | 12 (better) |
| Valuation score | 1 (better) | 0 |
| Growth score | 2 | 4 (better) |
| Performance score | 3 | 3 |
| Health score | 2 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 189× |
| P/S | 1.9× (better) | 4.9× |
| P/B | 2.1× (better) | 5.4× |
| EV/EBITDA | 33.5× (better) | 162× |
| P/FCF | – | 54.6× |
| FCF yield | −4.8% | 1.8% (better) |
| Fair value | $15.78 | $8.00 |
| Margin of safety | −21.1% (better) | −611% |
| Growth | ||
| Revenue growth (TTM) | 14.0% (better) | 13.8% |
| Revenue growth, 5Y average | 11.8% | 20.9% (better) |
| Profitability | ||
| Gross margin | 63.3% | 76.7% (better) |
| Operating margin | 2.3% | 2.9% (better) |
| Net margin | −3.7% | 2.5% (better) |
| FCF margin | −9.2% | 9.0% (better) |
| Return on equity | −4.0% | 2.9% (better) |
| Return on invested capital | 1.3% | 3.9% (better) |
| Financial health | ||
| Debt / equity | 0.81 | 0.11 (better) |
| Net debt / EBITDA | 8.47 (better) | −7.40 |
| Interest coverage | 0.4× | 2.9× (better) |
| Current ratio | 4.42 (better) | 4.33 |
| Altman Z-score | 1.64 | 10.00 (better) |
| Piotroski F-score | 7 | 7 |
| Dividends and buybacks | ||
| Buyback yield | −0.81% | – |
| Shareholder yield | −0.81% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 94.9% | 104% |
| Held by insiders | 8.9% | 4.0% |
| Insider net buying, 12 months | −$12.1M | −$4.4M (better) |
| Short interest, % of float | 7.7% | 10.0% |
Go deeper
- AORT stock overview
- AORT income statement
- AORT valuation and score
- ATRC stock overview
- ATRC income statement
- ATRC valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.